SCHEMBL4636160

SCHEMBL4636160

CCOC(=O)c1cccc(O)c1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O

nearest known ligand 0.58

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SLC28A3 Q9HAS3 4/20 0.58
EPHX2 P34913 2/20 0.50
SLC5A1 P13866 2/20 0.50
HIF1A Q16665 1/20 0.49
ALDH1A1 P00352 1/20 0.49
SLC5A2 P31639 1/20 0.47
TYR P14679 1/20 0.46
POLB P06746 1/20 0.46
CA12 O43570 1/20 0.45
CA1 P00915 1/20 0.45
CA7 P43166 1/20 0.45
CA9 Q16790 1/20 0.45
CA13 Q8N1Q1 1/20 0.45
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4635870 0.91 SLC28A3 (0.56) SLC28A3EPHX2SLC5A1HIF1AALDH1A1
SCHEMBL4636191 0.89 SLC28A3 (0.61) SLC28A3EPHX2SLC5A1HIF1ASLC5A2
SCHEMBL4635629 0.86 SLC28A3 (0.57) SLC28A3EPHX2SLC5A1HIF1AALDH1A1
SCHEMBL941049 0.85 SLC28A3 (0.60) SLC28A3SLC5A1HIF1ASLC5A2TYR
SCHEMBL4635305 0.85 SLC28A3 (0.61) SLC28A3EPHX2SLC5A1HIF1AALDH1A1
SCHEMBL943236 0.84 SLC28A3 (0.74) SLC28A3SLC5A1HIF1ASLC5A2TYR
SCHEMBL30803032 0.82 SLC28A3 (0.53) SLC28A3EPHX2SLC5A1HIF1ASLC5A2
SCHEMBL29078207 0.80 SLC28A3 (0.64) SLC28A3EPHX2SLC5A1HIF1AALDH1A1
SCHEMBL943281 0.80 NPC1 (0.57) SLC5A1SLC5A2TYRPOLBCA12
SCHEMBL941510 0.80 NPC1 (0.65) SLC28A3TYRPOLBCA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1932514-B1 PHARMACEUTICAL PREPARATION FOR EXTERNAL APPLICATION TO SKIN COMPRISING PHOSPHORYLATED SUGAR EZAKI GLICO CO (JP) 2018-11-14 EP disclosed
US-20140023602-A1 EXTERNAL PREPARATION FOR SKIN CONTAINING A PHOSPHORYLATED SACCHARIDE EZAKI GLICO CO., LTD. (JP) 2014-01-23 US disclosed
US-20080274068-A1 External Preparation for Skin Containing a Phosphorlated Saccharide EZAKI GLICO CO., LTD. (JP) 2008-11-06 US disclosed
EP-1932514-A1 PHARMACEUTICAL PREPARATION FOR EXTERNAL APPLICATION TO SKIN COMPRISING PHOSPHORYLATED SUGAR Ezaki Glico Co., Ltd. (JP) 2008-06-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140023602-A1 EXTERNAL PREPARATION FOR SKIN CONTAINING A PHOSPHORYLATED SACCHARIDE SI, CUTA, CD44 SLC28A3 1164/4885EPHX2 4134/4885SLC5A1 723/4885
US-20080274068-A1 External Preparation for Skin Containing a Phosphorlated Saccharide CUTA, SI, CD44 SLC28A3 977/4885EPHX2 4123/4885SLC5A1 589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.